High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This trail is designed to assess the efficacy and safety of high dose Iconitib combined with
SRS for NSCLC patients harboring EGFR mutation with brain metastases.